Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey
Alice Indini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Francesco Grossi(University of Insubria), Claudio Zamagni(Policlinico S.Orsola-Malpighi), Cinzia Ortega(Candiolo Cancer Institute), Monica Giordano(Ospedale Sant'Anna), A. Scanni, Bruno Daniele(Azienda Ospedaliera G.Rummo), Giammaria Fiorentini(Ospedali Riuniti Marche Nord), Livio Blasi, Luigi Cavanna(University of Pavia), Luisa Fioretto(Ospedale SS. Annunziata), C. Aschele(Ospedale San Carlo), Mario Clerico(Ospedale degli Infermi), Graziella Pinotti(Medica (Italy)), Vincenzo Montesarchio(CTO Hospital)
Cited by 111
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.1k
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
|Journal of Clinical Oncology|2011|763
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751